Canadian Large Cap Leaders Split Corp. Declares Distribution

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Canadian Large Cap Leaders Split Corp. (the “Company”) (TSX: NPS, NPS.PR.A) announces distribution payable on October 10, 2025, to Class A and Preferred Shareholders of record at the close of business on September 29, 2025.

Share Class	Ticker	Amount Per Share
Class A	NPS	0.12500
Preferred	NPS.PR.A	0.1875

The Company offers a distribution reinvestment plan (“DRIP”) for Class A shareholders which provides the ability to automatically reinvest distributions, commission free, and realize the benefits of compound growth. Class A shareholders can enroll in the DRIP program by contacting their investment advisor.

About Ninepoint Partners

Ninepoint Partners LP is the Manager, Portfolio Manager and Promoter of the Company and provides all administrative services required by the Company.

Based in Toronto, Ninepoint Partners LP is one of Canada’s leading alternative investment management firms overseeing approximately $7 billion in assets under management and institutional contracts. Committed to helping investors explore innovative investment solutions that have the potential to enhance returns and manage portfolio risk, Ninepoint offers a diverse set of alternative strategies spanning Equities, Fixed Income, Alternative Income, Real Assets, F/X and Digital Assets.

For more information on Ninepoint Partners LP, please visit www.ninepoint.com or please contact us at 416.362.7172 or 1.888.362.7172 or [email protected].

Sales Inquiries:

Ninepoint Partners LP
Neil Ross
416-945-6227
[email protected] 

Source: Ninepoint Partners LP

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• InterDigital to Spotlight Innovation Underpinning Interactive AR and Energy-Efficient Video Streaming at 2026 FOKUS Media Web Symposium
• Cendyn unveils AI-native infrastructure tackling hotels' invisibility cliff
• Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors